PHARMACOTHERAPY OF PAIN

Pain management through pharmacotherapy is a central aspect of medical care, designed to reduce suffering, restore daily function, and improve overall quality of life. Treatment strategies depend on the type of pain (nociceptive, neuropathic, or neoplastic), as well as its intensity and duration (acute vs. chronic). The World Health Organization’s (WHO) analgesic ladder provides the framework for a gradual escalation of therapy—from non-opioid agents such as acetaminophen and NSAIDs, to weaker opioids, and finally to stronger opioids when required. Neuropathic pain is typically treated with first-line agents like antidepressants (e.g., amitriptyline, duloxetine) and anticonvulsants (e.g., gabapentin, pregnable). Current practice emphasizes multimodal analgesia, combining drugs with different mechanisms to enhance effectiveness and reduce side effects. Key challenges include addressing opioid-related harms such as tolerance, dependence, and misuse. Modern approaches therefore prioritize personalized, risk-based treatment plans, increasingly integrating non-drug therapies to improve long-term outcomes. Background: Pain is a multifaceted condition that poses significant challenges in clinical management. Pharmacological therapy remains the mainstay of treatment for most pain types. Objective: To summarize the essential principles, major drug classes, and current practices in pain pharmacotherapy. Methods: A stepwise, mechanism-based model is applied, with treatment tailored according to pain type (acute vs. chronic; nociceptive vs. neuropathic) and patient factors. Results: Non-opioid agents (NSAIDs, acetaminophen): first-line for mild to moderate pain. Opioids: indicated for severe acute pain or cancer pain, with caution in long-term use. Adjuvants (antidepressants, anticonvulsants): central in neuropathic pain therapy. Multimodal analgesia is highlighted as the preferred strategy to enhance outcomes and minimize risks. Conclusion: Effective pharmacotherapy requires an individualized, multimodal approach that balances analgesic benefits against adverse effects, particularly opioid-related issues. Future trends point toward personalized medicine and greater integration of pharmacological and non-drug treatments.